Cancer
Conditions
Keywords
Magnetic Resonance Spectroscopy, Lactate
Brief summary
This project is designed to investigate whether measurements of lactate in tumours, made using a magnetic resonance technique similar to MRI, is an effective non-invasive method to detect whether some new targeted drugs are having their desired effect. The study hypothesis is that by using magnetic resonance spectroscopy techniques, we will be able to observe changes in tumour lactate levels in vivo, in response to treatment.
Interventions
DEVICEMagnetic Resonance Imaging (MRI)
Magnetic Resonance Spectroscopy
Sponsors
Cancer Research UK
Institute of Cancer Research, United Kingdom
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Cohort 1:lymphoma patients * minimum lesion size of 2cm * not pretreated but scheduled to be treated with CHOP (Cyclophosphamide, Hydroxydaunomycin,Oncovin and Prednisolone) Cohort 2:Colorectal patients * metastatic disease of at least 2cm * not pretreated Cohort 3:Phase 1 Drug Development * minimum lesion size at least 2cm Cohort 4: Brain * primary brain tumours receiving radiotherapy and temozolomide * cerebral lymphoma receiving standard chemotherapy
Exclusion criteria
* MRI incompatible metal implants * Claustrophobia * Inability to tolerate a 40 minute MRI scan
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between changes in MRS lactate measurements at two time points after treatment and clinical response | 7 and 21 days post treatment |
Secondary
| Measure | Time frame |
|---|---|
| Reproducibility of MRS lactate measurement | Two baseline measurements taken at day -7 to 0 pre-treatment |
Other
| Measure | Time frame |
|---|---|
| Correlation between changes in post treatment MRS lactate measurements and serum lactate dehydrogenase | Baseline and 7 and 21 days post treatment |
Countries
United Kingdom
Outcome results
None listed